A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
A phase 3 trial of Nemtabrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). is a phase 3 interventional study registered as NCT05947851 by Merck Sharp & Dohme LLC, with 735 participants planned, started 2023-08-08 and due to reach its primary completion in 2032-06-01. Interventions recorded: Nemtabrutinib, Venetoclax and Rituximab.
Similar pages
not linked directly; found by shared links- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Nemtabrutinib, Rituximab, Chronic lymphocytic leukaemia, Merck & Co. (MSD) and the tag pipeline.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Rituximab, Venetoclax, Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shares Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.